Evogene grants director Nir Nimrodi 10,000 options

Q: How many options did EVGN director Nir Nimrodi receive?

Nir Nimrodi received 10,000 stock options on September 4, 2026, under Evogene Ltd.’s 2021 Share Incentive Plan.

The director's options vest 25% each quarter and are scheduled to be fully vested by September 4, 2027.

(Neutral)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Evogene Ltd. director Nir Nimrodi received 10,000 stock options on September 4, 2026, under the company’s 2021 Share Incentive Plan. The options have an exercise price of NIS 1.75 per share, equivalent to $0.58 per share, vest 25% per quarter beginning on the grant date, become fully vested by September 4, 2027, and expire September 4, 2036.

The filing also lists existing direct options covering 5,625 ordinary shares at an $11.00 exercise price, expiring April 20, 2030; 1,800 shares each at $10.20, $6.40 and $6.60, expiring September 15, 2032, May 11, 2033 and June 15, 2034; and 10,000 shares at $1.29, expiring August 18, 2035.

Insider Trade Summary

Grant/Award: 10,000 shares

Grant/Award 6 txns

Insider Nimrodi Nir

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy) ^{F1, F2, F3}	10,000	$0.00	$0.00
holding	Stock Option (right to buy) ^F4	--	--	--
holding	Stock Option (right to buy) ^F4	--	--	--
holding	Stock Option (right to buy) ^F4	--	--	--
holding	Stock Option (right to buy) ^F4	--	--	--
holding	Stock Option (right to buy) ^F4	--	--	--

Holdings After Transaction: Stock Option (right to buy) — 31,025 contracts for 21,025 underlying shares (Direct)

Footnotes (4)

F1. The exercise price of the stock options to purchase Ordinary Shares of the Issuer (the "Options") is New Israeli Shekels ("NIS") 1.75 per share, which is equivalent to $0.58 per share based on the representative exchange rate of NIS 3.0050 per U.S. dollar published by the Bank of Israel on September 4, 2026, the grant date.
F2. The transaction reported in this row consists of the grant by the Issuer's board of directors to the Reporting Person of 10,000 Options. The Options were granted pursuant to, and are subject to the terms of, the Issuer's 2021 Share Incentive Plan.
F3. The Options vest and become exercisable on a quarterly basis (25% per quarter) commencing on the grant date of September 4, 2026, such that they will be fully vested by September 4, 2027, the one-year anniversary of the grant date.
F4. There were no transactions effected in respect of the securities reported in this row, and the holdings in this row are being included for informational purposes only.

Key Figures

Options granted: 10,000 options Exercise price: NIS 1.75 per share, equivalent to $0.58 per share Vesting schedule: 25% per quarter +5 more

8 metrics

Options granted 10,000 options Granted to director Nir Nimrodi on September 4, 2026

Exercise price NIS 1.75 per share, equivalent to $0.58 per share Options granted September 4, 2026

Vesting schedule 25% per quarter Beginning on the grant date; fully vested by September 4, 2027

Existing options 5,625 underlying ordinary shares at an $11.00 exercise price Expiration date: April 20, 2030

Existing options 1,800 underlying ordinary shares at a $10.20 exercise price Expiration date: September 15, 2032

Existing options 1,800 underlying ordinary shares at a $6.40 exercise price Expiration date: May 11, 2033

Existing options 1,800 underlying ordinary shares at a $6.60 exercise price Expiration date: June 15, 2034

Existing options 10,000 underlying ordinary shares at a $1.29 exercise price Expiration date: August 18, 2035

Key Terms

2021 Share Incentive Plan, vest, exercisable

3 terms

vest financial

"Options vest and become exercisable on a quarterly basis"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

exercisable financial

"become exercisable on a quarterly basis"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many options did EVGN director Nir Nimrodi receive?

Nir Nimrodi received 10,000 stock options on September 4, 2026, under Evogene Ltd.’s 2021 Share Incentive Plan.

What are the vesting and exercise terms for EVGN's option grant?

The options have an exercise price of NIS 1.75 per share, equivalent to $0.58 per share. They vest 25% per quarter beginning on September 4, 2026, and become fully vested by September 4, 2027.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 09/30/2026 - 08:09 AM Accepted by SEC EDGAR 09/30/2026 - 08:09 AM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Nimrodi Nir

(Last)

(First)

(Middle)

291 CHINQUAPIN AVE

(Street)

CARLSBAD

CALIFORNIA

92008

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Evogene Ltd. [ EVGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (right to buy)	$0.58⁽¹⁾	09/04/2026		A⁽²⁾		10,000		⁽³⁾	09/04/2036	Ordinary Shares	10,000	$0	10,000	D
Stock Option (right to buy)⁽⁴⁾	$11							04/20/2021	04/20/2030	Ordinary Shares	5,625		5,625	D
Stock Option (right to buy)⁽⁴⁾	$10.2							09/15/2023	09/15/2032	Ordinary Shares	1,800		1,800	D
Stock Option (right to buy)⁽⁴⁾	$6.4							05/11/2024	05/11/2033	Ordinary Shares	1,800		1,800	D
Stock Option (right to buy)⁽⁴⁾	$6.6							06/15/2025	06/15/2034	Ordinary Shares	1,800		1,800	D
Stock Option (right to buy)⁽⁴⁾	$1.29							08/18/2026	08/18/2035	Ordinary Shares	10,000		10,000	D

Explanation of Responses:

1. The exercise price of the stock options to purchase Ordinary Shares of the Issuer (the "Options") is New Israeli Shekels ("NIS") 1.75 per share, which is equivalent to $0.58 per share based on the representative exchange rate of NIS 3.0050 per U.S. dollar published by the Bank of Israel on September 4, 2026, the grant date.

2. The transaction reported in this row consists of the grant by the Issuer's board of directors to the Reporting Person of 10,000 Options. The Options were granted pursuant to, and are subject to the terms of, the Issuer's 2021 Share Incentive Plan.

3. The Options vest and become exercisable on a quarterly basis (25% per quarter) commencing on the grant date of September 4, 2026, such that they will be fully vested by September 4, 2027, the one-year anniversary of the grant date.

4. There were no transactions effected in respect of the securities reported in this row, and the holdings in this row are being included for informational purposes only.

Remarks:

Exhibit 24.1 - Power of Attorney.

	/s/ Nitsan Deutsch, attorney-in-fact	09/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR